Resolve Therapeutics Announces Publication of Lupus Clinical Trial Results

2024-02-12
PRNewswire
临床2期临床结果siRNA
MIAMI, Feb. 12, 2024 /PRNewswire/ -- Resolve Therapeutics, a mid-stage clinical development biotechnology company pioneering first-in-class therapies for autoimmune diseases, today announced the publication of results from its phase 2a clinical trial of RSLV-132 in patients with Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine.
The publication entitled "Evaluation of RNase therapy in systemic lupus erythematosus: a randomized phase 2a clinical trial of RSLV-132" describes a proof-of-concept study in SLE patients with moderate-severe cutaneous disease activity.  The findings suggest that patients with Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2k) scores above nine respond preferentially to digestion of extracellular RNA as compared to patients with lower SLEDAI-2k scores less than nine.
"We would like to express our deepest gratitude to the patients that participated in the study" commented Dr. James Posada chief executive officer of Resolve Therapeutics.  "Mounting evidence substantiates the importance of extracellular RNA as a drug target in autoimmune diseases such as SLE and Sjogren's.  Our study demonstrates the potential benefit of digesting circulating pathogenic RNA in selected SLE patients with active systemic disease and circulating RNA-containing autoantibodies" added Dr. Posada.
About RSLV-132
RSLV-132 is a non-immunosuppressive, biologic drug comprised of catalytically active human RNase1 fused to the Fc region of human IgG1.  It is designed to remain in serum circulation and digest extracellular pathogenic RNA in patients with autoimmune diseases.  RNA is the primary trigger of interferon production and drives chronic inflammation in autoimmune diseases such as SLE and Sjogren's, therefore removing it from circulation may decrease inflammation and improve the symptoms associated with these autoimmune diseases.
Resolve is a private biotech company pioneering a completely new approach to autoimmune disease.  The company is leveraging the extensive body of scientific discoveries that demonstrate the central role of pathogenic RNA molecules in autoimmune disease.  Resolve is actively developing RSLV-132 in mid-stage clinical development programs icluding SLE, Sjogren's syndrome, and post-acute sequelae of SARS-CoV-2 infection (PASC).  For more information please visit: https://resolvetherapeutics.com/
Contact:
James Posada
208-727-7010
[email protected]
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。